[Association of kynurenine-3-monooxygenase gene with schizophrenia]. 2014

V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev

Neurotoxic products produced during tryptophan metabolism via the kynurenine pathway could be involved in schizophrenia pathogenesis. It has been shown that kynurenine-3-monooxygenase (KMO) is indirectly involved in these products' formation. KMO polymorphic loci rs2275163 (C/T) and rs1053230 (A/G) were examined in 187 schizophrenia patients and 229 healthy subjects. A genetic combination of allele T and genotype GG was observed more often in a patient group compared with healthy controls (p = 0.003, OR 2.0 (95% CI 1.2-2.9). In the latter group, this combination was associated with schizophrenia endophenotype (p = 0.04), which manifested in a higher expression of schizotypal personality traits assessed using the MMPI test.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D050601 Kynurenine 3-Monooxygenase An NADPH-dependent flavin monooxygenase that plays a key role in the catabolism of TRYPTOPHAN by catalyzing the HYDROXYLATION of KYNURENINE to 3-hydroxykynurenine. It was formerly characterized as EC 1.14.1.2 and EC 1.99.1.5. Kynurenine 3-Hydroxylase,Kynurenine Hydroxylase,L-Kynurenine-3-Hydroxylase,3-Hydroxylase, Kynurenine,3-Monooxygenase, Kynurenine,Hydroxylase, Kynurenine,Kynurenine 3 Hydroxylase,Kynurenine 3 Monooxygenase,L Kynurenine 3 Hydroxylase
D020641 Polymorphism, Single Nucleotide A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population. SNPs,Single Nucleotide Polymorphism,Nucleotide Polymorphism, Single,Nucleotide Polymorphisms, Single,Polymorphisms, Single Nucleotide,Single Nucleotide Polymorphisms

Related Publications

V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
June 2006, Genes, brain, and behavior,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
July 2011, Archives of general psychiatry,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
April 2011, Schizophrenia research,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
December 2014, Schizophrenia research,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
December 2023, Molecular neurobiology,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
January 2022, Molecules (Basel, Switzerland),
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
April 2013, Nature,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
January 2012, Journal of psychiatry & neuroscience : JPN,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
January 2015, Frontiers in psychiatry,
V E Golimbet, and T V Lezheiko, and M V Alfimova, and L I Abramova, and N V Kondrat'ev
January 2000, Redox report : communications in free radical research,
Copied contents to your clipboard!